Octapharma USA Presents Research on Congenital & Acquired Bleeding Disorders at ASH Annual Meeting
Retrieved on:
Thursday, December 3, 2020
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Surgery, Health, Clinical trials, Blood, Anatomy, Congenital disorders, Coagulation system, Octapharma, Congenital afibrinogenemia, Fibrinogen, Coagulopathy, Aminocaproic acid, Bleeding, American Society of Hematology, Factor I deficiency
Octapharma USA will present multiple clinical research posters focused on the efficacy and safety of fibryga , Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use in the treatment of congenital and acquired bleeding disorders during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, a virtual medical congress to be held December 5 8.
Key Points:
- Octapharma USA will present multiple clinical research posters focused on the efficacy and safety of fibryga , Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use in the treatment of congenital and acquired bleeding disorders during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, a virtual medical congress to be held December 5 8.
- Additionally, Octapharma will present fibryga research evaluating the products hemostatic efficacy in acquired fibrinogen deficiency, a condition affecting non-surgical and surgical bleeding patients, including cardiac surgery, post-partum hemorrhage and trauma patients.
- Octapharma is determined to advance clinical research and treatment options for people with life-threatening bleeding disorders, including Factor 1 deficiency and other rare conditions, said Octapharma USA President Flemming Nielsen.
- A favorable safety profile was seen for the treatment of patients with congenital afibrinogenemia with fibryga.